阿普米司特治疗中重度银屑病104周安全性与疗效:LIBERATE研究
结果显示阿普米司特在皮肤、头皮、甲及患者报告结局方面疗效持续,安全性与此前已知特征一致。
要点
- 阿普米司特治疗104周时PASI-75应答率在50.7%、45.9%和51.9%之间维持。
- 头皮和甲受累及瘙痒、生活质量均获得持续改善。
- 延长暴露未增加腹泻、恶心等不良事件的发生率。
核心结论
- 阿普米司特在中重度斑块状银屑病患者中104周内对皮肤、头皮、甲及患者报告结局显示显著且持续的改善。
- 安全性与此前已知的阿普米司特安全性特征一致。
研究设计与样本
- 第16周后全部患者继续或换用阿普米司特治疗至第104周(延伸期)。
- 延伸期纳入226例患者,分为安慰剂/阿普米司特组(n=73)、阿普米司特/阿普米司特组(n=74)和依那西普/阿普米司特组(n=79)。
主要发现
- 第104周时,三组分别有50.7%、45.9%和51.9%的患者维持PASI评分较基线改善≥75%(基于末次观测结转分析)。
- 各组中50.0%-59.2%的患者达到头皮医生整体评估(ScPGA)0分(清除)或1分(极轻微)。
- 甲银屑病严重指数(NAPSI)较基线平均变化为-48.1%至-51.1%。
- 66.0%-72.5%的患者达到皮肤病生活质量指数(DLQI)≤5分。
- 瘙痒视觉模拟量表(VAS)较基线平均变化为-24.4至-32.3。
临床怎么用
- 对于生物制剂初治的中重度斑块状银屑病患者,阿普米司特可作为长期治疗选择之一,兼顾皮肤、头皮、甲及瘙痒和生活质量改善。
- 由依那西普换用阿普米司特后疗效可维持,转换治疗时需关注长期安全性监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Apremilast, an oral phosphodiesterase-4 inhibitor, has demonstrated efficacy in patients with moderate to severe psoriasis. OBJECTIVE: To evaluate long-term efficacy and safety of apremilast in biologic-naive patients with moderate to severe plaque psoriasis and safety of switching from etanercept to apremilast in the phase 3b LIBERATE trial. METHODS: Two hundred fifty patients were randomized to placebo, apremilast 30 mg BID or etanercept 50 mg QW through Week 16; thereafter, all patients continued or switched to apremilast through Week 104 (extension phase). Skin, scalp and nail involvement at Weeks 16, 52 and 104 were assessed using the Psoriasis Area and Severity Index (PASI; 0-72), Scalp Physician Global Assessment (ScPGA; 0-5) and Nail Psoriasis Severity Index (NAPSI; 0-8); patient-reported outcomes (PROs) were assessed using the Dermatology Life Quality Index (DLQI; 0-32) and pruritus visual analog scale (VAS; 0-100 mm). RESULTS: The apremilast-extension phase (Weeks 16-104) included 226 patients in the placebo/apremilast (n = 73), apremilast/apremilast (n = 74) and etanercept/apremilast (n = 79) groups, and at Week 104, 50.7%, 45.9% and 51.9% of these patients, respectively, maintained ≥75% reduction from baseline in PASI score (based on last-observation-carried-forward analysis). Across treatment groups, ScPGA 0 (clear) or 1 (minimal) was achieved by 50.0%-59.2% of patients; NAPSI mean change from baseline was -48.1% to -51.1%; DLQI score ≤5 was achieved by 66.0%-72.5% of patients; and pruritus VAS mean change from baseline was -24.4 to -32.3. AEs in ≥5% of patients (diarrhoea, nausea, nasopharyngitis, upper respiratory tract infection and headache) did not increase with prolonged apremilast exposure. CONCLUSIONS: Apremilast demonstrated significant and sustained improvements in skin, scalp, nails and PROs (pruritus and quality of life) over 104 weeks in patients with moderate to severe plaque psoriasis. Safety was consistent with the known safety profile of apremilast.
引用
- Reich K, Gooderham M, Bewley A, et al. Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study. J Eur Acad Dermatol Venereol. 2018. PMID: 29220542. doi:10.1111/jdv.14738
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。